Royalty Pharma Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
Royalty Pharma yıllık ortalama 11.7% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 9.7% annual. Gelirler growing yılda ortalama 0.9% oranında artmaktadır. Royalty Pharma'in özkaynak karlılığı 13.7% ve net marjı 33.9%'dir.
Anahtar bilgiler
11.69%
Kazanç büyüme oranı
9.54%
EPS büyüme oranı
| Pharmaceuticals Sektör Büyümesi | 5.95% |
| Gelir büyüme oranı | 0.93% |
| Özkaynak getirisi | 13.67% |
| Net Marj | 33.86% |
| Son Kazanç Güncellemesi | 31 Mar 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Seeking Alpha • May 16
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
Summary Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7 billion increasingly appears conservative. Recent funding agreements with Johnson & Johnson, alongside prior collaborations with Biogen, Merck, and Teva, strengthen Royalty Pharma’s positioning. Capital flexibility and buybacks remain meaningful tailwinds. We remain buyers. Read the full article on Seeking Alpha
Anlatı Güncellemesi • May 02
RPRX: Royalty Deals And Buybacks Will Shape Balanced Forward Outlook
Analysts have raised their blended price target on Royalty Pharma by several dollars to around the mid $40s, citing refined models that factor in slightly higher projected revenue growth, modestly lower profit margins, and continued benefits from recent royalty and financing deals such as the $250m Zymeworks agreement. Analyst Commentary Recent research on Royalty Pharma centers on how the updated price targets line up with the company’s deal pipeline, especially the $250m Zymeworks transaction.
Anlatı Güncellemesi • Apr 17
RPRX: Diversified Royalty Portfolio And Recent Deals Will Support Future Upside
Analysts have nudged their price targets for Royalty Pharma modestly higher, with the average fair value estimate moving from about $59.28 to $60.61. They point to the company's diversified royalty portfolio, favorable deal terms such as the $250m Zymeworks financing, and the broader growth of the biopharma royalty market.Anlatı Güncellemesi • Apr 03
RPRX: Royalty Deals And Dividend Policy Will Shape Balanced Forward Outlook
Analysts have raised the fair value estimate for Royalty Pharma to $46.00 from $40.86, citing updated models that reflect perceived strengths in its biopharma royalty exposure, portfolio diversification, and recent deal activity. Analyst Commentary Recent Street research around Royalty Pharma highlights both constructive and cautious views, giving you a mixed picture of how professionals are thinking about the stock.
Anlatı Güncellemesi • Mar 19
RPRX: Royalty Deals And Buybacks Will Support Future Upside
Analysts have lifted their price target on Royalty Pharma to $51.56 from $51.00, citing updated Street views on its biopharma royalty exposure and recent deal activity as key supports for the revised fair value estimate. Analyst Commentary Recent Street commentary on Royalty Pharma highlights a mix of optimism around its royalty portfolio and business model, alongside some areas where investors may want to stay cautious on execution and deal risk.Anlatı Güncellemesi • Mar 05
RPRX: Royalty Platform And Portfolio Diversification Will Drive Future Upside Potential
Analysts have nudged their targets higher on Royalty Pharma, with the consensus fair value estimate moving from $56.00 to about $59.28. They cite expectations for the company to benefit from growth in the biopharma royalty market, differentiation from competitors, and a more diversified portfolio.Anlatı Güncellemesi • Feb 19
RPRX: Higher P/E Expectations And Buybacks Will Support Future Upside
Analysts have lifted their average price target on Royalty Pharma from about $46 to roughly $51, citing updated assumptions for fair value, discount rate, growth, margins, and a higher future P/E multiple as key drivers behind the move. Analyst Commentary Recent research coverage on Royalty Pharma has centered on refreshed models for fair value and updated assumptions around discount rates, growth, margins, and future P/E multiples.Analiz Makalesi • Feb 11
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Anlatı Güncellemesi • Feb 05
RPRX: Pending XenoTherapeutics Deal And Dividend Increase Will Shape Near-Term Returns
Analysts have raised their price targets on Royalty Pharma by about $2 to an updated fair value of US$40.86, citing slightly higher long term revenue growth assumptions, a modestly higher future P/E multiple, and largely unchanged discount rate and profit margin inputs. Analyst Commentary Recent research on Royalty Pharma has been mixed, with some firms updating ratings and price targets around the company’s agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Analiz Makalesi • Jan 22
Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
Royalty Pharma plc's ( NASDAQ:RPRX ) dividend will be increasing from last year's payment of the same period to $0.235...Anlatı Güncellemesi • Jan 21
RPRX: Pending XenoTherapeutics Deal And Hold Downgrade Will Limit Near-Term Upside
Analysts have trimmed their price expectations for Royalty Pharma, citing a revised fair value of $38.00 per share. This reflects updated views on revenue growth, profit margins, and future P/E multiples following the announced acquisition by XenoTherapeutics and the recent downgrade to Hold.Anlatı Güncellemesi • Jan 07
RPRX: Agreed XenoTherapeutics Deal Will Highlight Upside In Royalty Portfolio Earnings Power
Analysts have nudged their fair value target for Royalty Pharma up to US$56.00 from US$55.00. This reflects updated assumptions on slower revenue growth, higher margins and a lower future P/E, while also factoring in the recent downgrade to Hold following the agreed acquisition by XenoTherapeutics at an estimated US$1.82 per share.Anlatı Güncellemesi • Dec 15
RPRX Pending XenoTherapeutics Deal Will Anchor Shares Near Buyout Price
Analysts have nudged their price target on Royalty Pharma up by $1, to $38. This reflects modestly stronger revenue growth assumptions, offset by a slightly higher discount rate and lower projected profit margins, and incorporates the limited upside they see given the pending acquisition by XenoTherapeutics.Anlatı Güncellemesi • Dec 01
RPRX: Share Buybacks Will Drive Value Upon Acquisition Completion
Analysts have revised Royalty Pharma's price target slightly upward from $45.54 to $45.98. They note that the pending acquisition by XenoTherapeutics has reduced uncertainty around the company’s valuation.Anlatı Güncellemesi • Nov 17
RPRX: Share Buybacks And Acquisition Will Drive Outperformance After Downgrade
Analysts have raised Royalty Pharma's price target from $44.10 to $45.54, reflecting updated expectations for revenue growth. However, profit margins are anticipated to decrease following recent acquisition developments.Anlatı Güncellemesi • Nov 02
RPRX: Upcoming Licensing Deals And Share Buybacks Will Drive Long-Term Upside
Narrative Update on Royalty Pharma: Analyst Price Target Revision Analysts have lowered their fair value estimate for Royalty Pharma from $44.86 to $44.10 per share. This revision is based on updated modeling of revenue growth and profit margins.Anlatı Güncellemesi • Sep 04
Emerging Therapies And Licensing Will Expand Royalty Opportunities
Analysts maintain a positive outlook for Royalty Pharma, citing resilience amid sector underperformance, limited exposure to policy and macroeconomic risks, and anticipated seasonal strength, with the consensus price target unchanged at $43.27. Analyst Commentary Bullish analysts expect Q2 to be seasonally strong for large biopharma companies, supporting near-term performance.Analiz Makalesi • Jul 06
Benign Growth For Royalty Pharma plc (NASDAQ:RPRX) Underpins Its Share Price
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 19x, you may...Analiz Makalesi • May 31
Here's Why We Think Royalty Pharma (NASDAQ:RPRX) Is Well Worth Watching
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Feb 13
Royalty Pharma: Delivering Growth With A Positive Story Ahead
Summary Royalty Pharma's Q4 results show portfolio receipts of $742 million and operating cash flow of $678 million, which demonstrate solid performance. MorphoSys bond redeployment further enhances higher-returning royalty opportunities. The company has a solid balance sheet with $1.4 billion in cash equivalents, which is worth considering. RPRX's valuation remains compelling, with a double-digit total yield (via buyback and dividend). Read the full article on Seeking AlphaSeeking Alpha • Jan 15
Royalty Pharma: Key Strategic Updates To Be Priced In
Summary Key strategic updates include acquiring RP Management LLC, simplifying the corporate structure, reducing costs, and enhancing shareholder alignment. A new $3 billion share repurchase program and a 5% dividend increase highlight strong capital allocation, maintaining financial flexibility and an investment-grade credit rating. The valuation remains compelling, with a 30% upside. Anticipated savings and buybacks suggest further EPS growth, reinforcing our overweight rating. Read the full article on Seeking AlphaSeeking Alpha • Nov 09
Royalty Pharma: Massive Opportunity Ahead
Summary Royalty Pharma's Q3 results met expectations, with a modest 2024 outlook increase, driven by strong portfolio performance and new royalty acquisitions. The CF franchise remains a key cash cow despite challenges, with Vertex's Venza triple development posing potential headwinds. With a compelling valuation, a $1 billion buyback, and a supportive pipeline, Royalty Pharma is a strong buy. Read the full article on Seeking AlphaGelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Royalty Pharma nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 31 Mar 26 | 2,441 | 826 | 708 | 441 |
| 31 Dec 25 | 2,378 | 771 | 663 | 452 |
| 30 Sep 25 | 2,350 | 766 | 554 | 402 |
| 30 Jun 25 | 2,305 | 1,022 | 492 | 352 |
| 31 Mar 25 | 2,264 | 1,094 | 290 | 52 |
| 31 Dec 24 | 2,264 | 859 | 237 | 2 |
| 30 Sep 24 | 2,266 | 1,145 | 228 | 2 |
| 30 Jun 24 | 2,238 | 673 | 229 | 52 |
| 31 Mar 24 | 2,239 | 799 | 222 | 52 |
| 31 Dec 23 | 2,355 | 1,135 | 250 | 52 |
| 30 Sep 23 | 2,324 | 184 | 264 | 102 |
| 30 Jun 23 | 2,361 | 255 | 257 | 77 |
| 31 Mar 23 | 2,359 | 332 | 261 | 77 |
| 31 Dec 22 | 2,237 | 43 | 227 | 177 |
| 30 Sep 22 | 2,247 | 507 | 200 | 230 |
| 30 Jun 22 | 2,259 | 466 | 198 | 295 |
| 31 Mar 22 | 2,278 | 602 | 191 | 298 |
| 31 Dec 21 | 2,289 | 620 | 183 | 200 |
| 30 Sep 21 | 2,286 | 783 | 187 | 104 |
| 30 Jun 21 | 2,239 | 972 | 189 | 19 |
| 31 Mar 21 | 2,195 | 493 | 187 | 21 |
| 31 Dec 20 | 2,122 | 495 | 182 | 26 |
| 30 Sep 20 | 2,008 | 1,745 | 155 | 34 |
| 30 Jun 20 | 1,934 | 1,863 | 130 | 52 |
| 31 Mar 20 | 1,880 | 2,052 | 117 | 68 |
| 31 Dec 19 | 1,814 | 2,349 | 103 | 83 |
| 31 Dec 18 | 1,795 | 1,378 | 62 | 393 |
| 31 Dec 17 | 1,598 | 1,210 | 106 | 118 |
Kaliteli Kazançlar: RPRX yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: RPRX 'nin mevcut net kar marjları (33.9%) geçen yılın (48.3%) değerinden daha düşüktür.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: RPRX şirketinin kazancı son 5 yılda yılda 11.7% oranında arttı.
Büyüme Hızlandırma: RPRX 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.
Kazançlar vs. Sektör: RPRX geçtiğimiz yıl negatif kazanç büyümesine ( -24.4% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( -5% ) karşılaştırmayı zorlaştırıyordu.
Özkaynak Getirisi
Yüksek ROE: RPRX 'nin Özsermaye Getirisi ( 13.7% ) düşük olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/21 09:30 |
| Gün Sonu Hisse Fiyatı | 2026/05/21 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Royalty Pharma plc 14 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Jason Matthew Gerberry | BofA Global Research |
| Geoffrey Meacham | Citigroup Inc |
| Prem Chulaki | CrispIdea |